News · 26 weeks70+13%
2026-03-012026-08-23
Mix3490d
- Insider19(56%)
- SEC Filings8(24%)
- Other4(12%)
- Leadership2(6%)
- Analyst1(3%)
Latest news
25 items- ANALYSTWedbush initiated coverage on Immunic with a new price targetWedbush initiated coverage of Immunic with a rating of Outperform and set a new price target of $45.00
- SECSEC Form SCHEDULE 13G filed by Immunic Inc.SCHEDULE 13G - IMMUNIC, INC. (0001280776) (Subject)
- SECSEC Form S-8 filed by Immunic Inc.S-8 - IMMUNIC, INC. (0001280776) (Filer)
- SECImmunic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- SECSEC Form 10-Q filed by Immunic Inc.10-Q - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness –– Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 –– Continued Preparations for Phase 3 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis, with Initiation Planned Later This Year –NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today r
- INSIDERSEC Form 4 filed by Director Ridloff Elena4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ridloff Elena3 - IMMUNIC, INC. (0001280776) (Issuer)
- PRImmunic Appoints Elena Ridloff to Board of Directors– Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple Sclerosis as well as Potential Regulatory Filings and Commercialization –NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Elena Ridloff, CFA to its Board of Directors, effective August 6, 2026. Ms. Ridloff brings more than two decades of experience driving financial strategy, corporate growth, and capital markets execution across the biopharmaceutical i
- SECImmunic Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic to Participate in Investor Conferences in JulyNEW YORK, July 9, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in July:July 14-15: Leerink Partners Therapeutics Forum. Erik Lundgren, Chief Executive Officer, Jason Tardio, President and Chief Operating Officer, Michael A. Panzara, M.D., M.P.H., Chief Medical Officer and Jessica Breu, Vice President Investor Relations and Communications at Immunic, will participate in one-on-one investor meetings at this conference in Boston. To schedule a meeting, please contact your Leerink representative or Jessica Breu at:
- INSIDERSEC Form 4 filed by Director Skerjanec Simona4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Rudick Richard Alan4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Phillips Barclay A4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Neermann Joerg4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Congleton Jon4 - IMMUNIC, INC. (0001280776) (Issuer)
- SECImmunic Inc. filed SEC Form 8-K: Leadership Update8-K - IMMUNIC, INC. (0001280776) (Filer)
- INSIDERSEC Form 4 filed by Director Congleton Jon4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Skerjanec Simona4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Rudick Richard Alan4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Howson Tamar D4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Whaley Glenn4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by President and COO Tardio Jason4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Neermann Joerg4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by Director Phillips Barclay A4 - IMMUNIC, INC. (0001280776) (Issuer)
IMUX FAQ
7 questionsWhat does Immunic Inc. do?
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from...Where does IMUX stock trade?
Immunic Inc. (IMUX) is listed on NASDAQ.What sector and industry is IMUX in?
Immunic Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Immunic Inc. go public?
Immunic Inc. (IMUX) completed its IPO in 2014.What are analysts saying about IMUX?
Immunic Inc. has had 8 recent analyst actions on file. The most recent action was from Wedbush: Outperform with a $4500.00 price target on 2026-08-17.What companies are similar to IMUX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IMUX side-by-side with any of them on Quantisnow.How can I track IMUX on Quantisnow?
Quantisnow aggregates Immunic Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMUX to receive live email and push alerts on every new disclosure.